Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title><jats:p>Histone acetylation plays an important role in regulating gene transcription and silencing in<jats:italic>Plasmodium falciparum</jats:italic>. Histone deacetylase (HDAC) inhibitors, particularly those of the hydroxamate class, have been shown to have potent<jats:italic>in vitro</jats:italic>activity against drug-resistant and -sensitive laboratory strains of<jats:italic>P. falciparum</jats:italic>, raising their potential as a new class of antimalarial compounds. In the current study, stage-specific<jats:italic>ex vivo</jats:italic>susceptibility profiles of representative hydroxamate-based HDAC inhibitors suberoylanilide hydroxamic acid (SAHA), 2-ASA-9, and 2-ASA-14 (2-ASA-9 and 2-ASA-14 are 2-aminosuberic acid-based HDAC inhibitors) were assessed in multidrug-resistant clinical isolates of<jats:italic>P. falciparum</jats:italic>(<jats:italic>n</jats:italic>= 24) and<jats:italic>P. vivax</jats:italic>(<jats:italic>n</jats:italic>= 25) from Papua, Indonesia, using a modified schizont maturation assay. Submicromolar concentrations of SAHA, 2-ASA-9, and 2-ASA-14 inhibited the growth of both<jats:italic>P. falciparum</jats:italic>(median 50% inhibitory concentrations [IC<jats:sub>50</jats:sub>s] of 310, 533, and 266 nM) and<jats:italic>P. vivax</jats:italic>(median IC<jats:sub>50</jats:sub>s of 170, 503, and 278 nM). Inverse correlation patterns between HDAC inhibitors and chloroquine for<jats:italic>P. falciparum</jats:italic>and mefloquine for<jats:italic>P. vivax</jats:italic>indicate species-specific susceptibility profiles for HDAC inhibitors. These HDAC inhibitors were also found to be potent<jats:italic>ex vivo</jats:italic>against<jats:italic>P</jats:italic>.<jats:italic>vivax</jats:italic>schizont maturation, comparable to that in<jats:italic>P. falciparum</jats:italic>, suggesting that HDAC inhibitors may be promising candidates for antimalarial therapy in geographical locations where both species are endemic. Further studies optimizing the selectivity and<jats:italic>in vivo</jats:italic>efficacy of HDAC inhibitors in<jats:italic>Plasmodium</jats:italic>spp. and defining drug interaction with common antimalarial compounds are warranted to investigate the role of HDAC inhibitors in antimalarial therapy.</jats:p>

Original publication





Antimicrobial Agents and Chemotherapy


American Society for Microbiology

Publication Date





961 - 966